IBBQ - ETF AI Analysis
Top Page
Invesco Nasdaq Biotechnology ETF (IBBQ)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Overall Performance
The ETF has shown strong gains so far this year and in recent months, indicating positive momentum in its biotechnology holdings.
Leading Biotech Companies at the Top
Several of the largest positions, including well-known biotech leaders, have delivered solid performance, helping support the fund’s returns.
Low Expense Ratio
The fund charges a relatively low fee, which means more of the investment gains can stay in investors’ pockets over time.
Negative Factors
Heavy Sector Concentration
Almost all of the ETF’s assets are in health care and biotechnology, so it is highly sensitive to swings in that single sector.
U.S.-Only Geographic Exposure
The fund is almost entirely invested in U.S. companies, offering little geographic diversification if the U.S. market faces challenges.
Mixed Performance Among Top Holdings
A few of the larger positions have shown weak or negative performance, which can drag on the fund even when other holdings are doing well.
IBBQ vs. SPDR S&P 500 ETF (SPY)
AUM77.50M
RegionNorth America
Expense Ratio0.19%
Beta0.80
IssuerInvesco
Inception DateJun 11, 2021
Dividend Yield0.8%
Asset ClassEquity
Index TrackedNASDAQ / Biotechnology
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume15,692
30 Day Avg. Volume23,151
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.21Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering250
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBBQ Summary
IBBQ is the Invesco Nasdaq Biotechnology ETF, which follows the Nasdaq Biotechnology Index. It focuses on U.S. health care companies in biotech and pharmaceuticals, including well-known names like Amgen and Gilead Sciences. These businesses work on new drugs and medical technologies, so investors may consider IBBQ if they want growth potential tied to medical innovation and a diversified basket of biotech stocks instead of picking single companies. A key risk is that biotech shares can be very volatile, so the ETF’s value can rise and fall sharply with news about drug approvals, clinical trials, and the overall stock market.
How much will it cost me?The Invesco Nasdaq Biotechnology ETF (IBBQ) has an expense ratio of 0.19%, meaning you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it tracks an index rather than requiring frequent adjustments by fund managers.
What would affect this ETF?The Invesco Nasdaq Biotechnology ETF (IBBQ) could benefit from advancements in biotechnology and pharmaceutical innovation, as well as increased global demand for cutting-edge healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or broader economic downturns that could impact funding for biotech firms. Its focus on U.S.-based companies and heavy exposure to the healthcare sector means it is particularly sensitive to changes in government healthcare policies and drug approval processes.
IBBQ Top 10 Holdings
IBBQ is essentially a bet on big U.S. biotech, with heavyweights like Amgen and Vertex doing much of the lifting as their shares have been generally rising this year. Gilead has been more steady, adding a quieter but reliable boost. On the flip side, Regeneron and Alnylam look like they’re losing steam, weighing on recent results. Smaller, fast-moving names like Revolution Medicines and Illumina have been on a strong upswing, injecting some excitement but also extra volatility. Overall, the fund is tightly focused on U.S. biotech innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 8.47% | $6.34M | $207.87B | 25.48% | 77 Outperform | |
| Vertex Pharmaceuticals | 7.92% | $5.93M | $121.09B | -0.33% | 78 Outperform | |
| Gilead Sciences | 7.35% | $5.50M | $161.66B | 14.53% | 78 Outperform | |
| Regeneron | 5.62% | $4.20M | $79.94B | 32.84% | 78 Outperform | |
| Revolution Medicines | 2.79% | $2.08M | $39.87B | 390.72% | 52 Neutral | |
| Illumina | 2.15% | $1.61M | $31.03B | 101.30% | 71 Outperform | |
| Biogen | 2.14% | $1.60M | $29.99B | 52.66% | 74 Outperform | |
| Alnylam Pharma | 2.11% | $1.58M | $27.50B | -47.48% | 60 Neutral | |
| Royalty Pharma | 1.82% | $1.36M | $33.65B | 50.92% | 79 Outperform | |
| Roivant Sciences | 1.72% | $1.29M | $24.50B | 189.49% | 58 Neutral |
IBBQ Technical Analysis
Positive
―
Price Trends
31.39
Positive
30.24
Positive
29.29
Positive
Market Momentum
0.23
Positive
57.43
Neutral
61.59
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBBQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.58, equal to the 50-day MA of 31.39, and equal to the 200-day MA of 29.29, indicating a bullish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 57.43 is Neutral, neither overbought nor oversold. The STOCH value of 61.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBBQ.
IBBQ Peer Comparison
Comparison Results
Performance Comparison
IBBQ
Invesco Nasdaq Biotechnology ETF
32.93
10.90
49.48%
PSCE
Invesco S&P SmallCap Energy ETF
―
―
―
QABA
First Trust NASDAQ ABA Community Bank Index Fund
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
ASD
Defiance Autism Impact ETF
―
―
―
TRUH
VanEck Healthcare TruSector ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents